Navigation Links
Protalix BioTherapeutics Announces Resignation of Board Members

CARMIEL, Israel, Dec. 5 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that two of its directors, Phillip Frost, M.D. and Jane H. Hsiao, Ph.D., have resigned from the Company's Board of Directors, effective immediately. Both resigned for personal reasons. Dr. Hsiao was a member of the compensation committee of the Board of Directors.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based expression system. Protalix's ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is enrolling and treating patients in its pivotal phase III clinical trial in Israel, the United States and other locations for its lead product candidate, prGCD, for its enzyme replacement therapy for Gaucher disease, a lysosomal storage disorder in humans, and has reached an agreement with the United States Food and Drug Administration on the final design of the pivotal phase III clinical trial through the FDA's Special Protocol Assessment (SPA) process. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.

Safe Harbor Statement:

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies and products under development, the identification of lead compounds, the successful preclinical development of our products, the completion of clinical trials, the review process of the FDA, foreign regulatory bodies and other governmental regulation, and other factors described in our filings with the Securities and Exchange Commission. The statements are valid only as of the date hereof and we disclaim any obligation to update this information.

For additional information, contact Protalix BioTherapeutics at:

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
2. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
(Date:11/24/2015)... ... , ... Young patients with a wide variety of dental needs can now ... Lele, who are pediatric dentists in Tucson, AZ . Unlike traditional treatment options ... causes minimal discomfort and bleeding to the patient during treatment and the following recovery ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Black Friday sale a week early, offering 40% off select bras and underwear ... apparel industry through both mobile fit technology and the latest fashion, quickly becoming ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced that Dr. Christine Milligan, ... East Asia Conference, to be held at the InterContinental Seoul COEX Hotel, Seoul, ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... when it comes to several aspects of orthopedic care. They have received recognition ... surgeries and general orthopedic care. , Becker's Hospital Review selected hospitals for ...
(Date:11/24/2015)... , ... November 24, 2015 , ... It takes only ... a business, it is critical that the first impression be positive and reflects business ... not likely to buy anything or want to return. They will also share their ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... November 24, 2015   ... dietician deliver s advice and insights on ... More than 50% of Dubai ... healthy according to the DHA   femMED launches comprehensive solutions ...    Dubai residents are not consuming enough to ...
(Date:11/24/2015)... Nov. 24, 2015 Abaxis, Inc. (NasdaqGS: ... and consumables for the medical, research, and veterinary markets ... Financial Officer, will present at the 27 th ... 2015 at 11:30 a.m. ET. The conference will be ... New York City . Abaxis, ...
(Date:11/24/2015)... Edelris announce today that they have out-licensed to ... UCBL and ENS-Lyon on a new treatment to cure Hepatitis ... B virus (HBV) infection is a major public health problem ... to 40% of them being at risk of developing chronic ... an effective preventive vaccine, the HBV infection is still rampant ...
Breaking Medicine Technology: